MPR

FDA Delays Decision on Subcutaneous Lecanemab Starting Dose

A major amendment has prompted the FDA to extend its review of subcutaneous lecanemab as a starting dose for early Alzheimer disease.

Biogen Inc.: Update on FDA Priority Review of LEQEMBI IQLIK (lecanemab-irmb) Subcutaneous Injection as a Starting Dose for Early Alzheimer's Disease

Eisai Co., Ltd. and Biogen Inc. (Nasdaq: BIIB) today announced that the U.S. Food and Drug Administration (FDA) has extended the review period ...

Eisai Co., Ltd.: Update on FDA Priority Review of LEQEMBI IQLIK (lecanemab-irmb) Subcutaneous Injection as a Starting Dose for Early Alzheimer's Disease

Eisai Co., Ltd. and Biogen Inc. (Nasdaq: BIIB) today announced that the U.S. Food and Drug Administration (FDA) ...
Nature

Enhanced hyaluronidase-based drug delivery

Biotechnology pioneer Halozyme has developed ENHANZE, a drug delivery technology that can enable and optimize the subcutaneous (SC) drug delivery of coadministered therapeutics. ENHANZE is based on ...